MX2022001961A - Medio de cultivo para induccion de hematopoyesis. - Google Patents
Medio de cultivo para induccion de hematopoyesis.Info
- Publication number
- MX2022001961A MX2022001961A MX2022001961A MX2022001961A MX2022001961A MX 2022001961 A MX2022001961 A MX 2022001961A MX 2022001961 A MX2022001961 A MX 2022001961A MX 2022001961 A MX2022001961 A MX 2022001961A MX 2022001961 A MX2022001961 A MX 2022001961A
- Authority
- MX
- Mexico
- Prior art keywords
- signaling pathways
- mediated signaling
- stimulate
- media
- cells
- Prior art date
Links
- 230000011132 hemopoiesis Effects 0.000 title abstract 2
- 230000006698 induction Effects 0.000 title abstract 2
- 239000001963 growth medium Substances 0.000 title 1
- 230000001404 mediated effect Effects 0.000 abstract 5
- 230000019491 signal transduction Effects 0.000 abstract 5
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 abstract 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 abstract 2
- 108010063738 Interleukins Proteins 0.000 abstract 2
- 102000015696 Interleukins Human genes 0.000 abstract 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 2
- 102000036693 Thrombopoietin Human genes 0.000 abstract 2
- 108010041111 Thrombopoietin Proteins 0.000 abstract 2
- 102100034196 Thrombopoietin receptor Human genes 0.000 abstract 2
- 108091008605 VEGF receptors Proteins 0.000 abstract 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 2
- 210000003566 hemangioblast Anatomy 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
- 108010002386 Interleukin-3 Proteins 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 108010002586 Interleukin-7 Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 210000000601 blood cell Anatomy 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/28—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from vascular endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1911955.1A GB201911955D0 (en) | 2019-08-20 | 2019-08-20 | Culture medium for haematopoietic induction |
| GBGB2012306.3A GB202012306D0 (en) | 2020-08-07 | 2020-08-07 | Culture medium for haematopoietic induction |
| PCT/EP2020/073407 WO2021032855A1 (en) | 2019-08-20 | 2020-08-20 | Culture medium for haematopoietic induction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001961A true MX2022001961A (es) | 2022-03-11 |
Family
ID=72234836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001961A MX2022001961A (es) | 2019-08-20 | 2020-08-20 | Medio de cultivo para induccion de hematopoyesis. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220275335A1 (https=) |
| EP (1) | EP4017969A1 (https=) |
| JP (1) | JP2022545415A (https=) |
| KR (1) | KR20220047375A (https=) |
| CN (1) | CN114341349A (https=) |
| AU (1) | AU2020333918A1 (https=) |
| BR (1) | BR112022003083A2 (https=) |
| CA (1) | CA3150037A1 (https=) |
| IL (1) | IL290602A (https=) |
| MX (1) | MX2022001961A (https=) |
| WO (1) | WO2021032855A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201911953D0 (en) * | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | T cell production fram RAG inacivated iPSCs |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| GB202102297D0 (en) * | 2021-02-18 | 2021-04-07 | Adaptimmune Ltd | Methods of Producing Haemogenic Endothelial Cells from Pluripotent Stem Cells |
| WO2022241558A1 (en) * | 2021-05-18 | 2022-11-24 | The University Of British Columbia | A method for producing blood progenitor and progenitor t cells, resulting cells and methods and uses thereof |
| GB202205572D0 (en) | 2022-04-14 | 2022-06-01 | Adaptimmune Ltd | Engineered T cells |
| GB202208545D0 (en) | 2022-06-10 | 2022-07-27 | Adaptimmune Ltd | Production of immune cells |
| WO2024050534A2 (en) * | 2022-09-01 | 2024-03-07 | Regents Of The University Of Minnesota | In vitro generated hematopoietic stem progenitor cells and t cells and methods of making and using the same |
| KR102566680B1 (ko) * | 2022-09-28 | 2023-08-14 | (주)포에버엔케이 | 면역세포 및 자연살해세포 배양을 위한 신규한 이중배양 제조방법 및 이의 용도 |
| WO2024107010A1 (ko) * | 2022-11-17 | 2024-05-23 | 주식회사 씨티셀즈 | 미분화 줄기세포로부터 자연 살해 세포로의 분화 방법 및 이의 용도 |
| CN118360247A (zh) * | 2023-01-19 | 2024-07-19 | 中国科学院动物研究所 | 一种iSCLP细胞及其制备方法和应用 |
| GB202318950D0 (en) | 2023-12-12 | 2024-01-24 | Adaptimmune Ltd | Production of immune cells |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6677631B2 (ja) * | 2013-03-13 | 2020-04-08 | ウイスコンシン アラムナイ リサーチ ファウンデーシヨンＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | 定義された条件下におけるヒト多能性幹細胞の造血内皮分化のための方法及び材料 |
| WO2015199127A1 (ja) * | 2014-06-24 | 2015-12-30 | 国立大学法人京都大学 | 中胚葉細胞および造血細胞の製造方法 |
| AU2016211671B2 (en) * | 2015-01-26 | 2022-05-26 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| CN108431211B (zh) * | 2015-10-20 | 2026-03-24 | 富士胶片细胞动力公司 | 通过遗传编程的多谱系造血前体细胞产生 |
| CA3003152A1 (en) * | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| WO2017100403A1 (en) * | 2015-12-08 | 2017-06-15 | Regents Of The University Of Minnesota | Human t cell derived from t cell-derived induced pluripotent stem cell and methods of making and using |
| US11141471B2 (en) * | 2016-04-25 | 2021-10-12 | Regen BioPharma, Inc. | Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells |
| WO2017193177A1 (en) * | 2016-05-13 | 2017-11-16 | Murdoch Childrens Research Institute | Haematopoietic stem/progenitor cells |
| CN110997904B (zh) * | 2017-03-21 | 2024-11-26 | 法国血液机构 | 改进造血移植物的方法 |
| SG11202006731VA (en) * | 2018-01-18 | 2020-08-28 | Agency Science Tech & Res | Method for differentiation of human pluripotent stem cell lines in suspension culture |
| GB201911953D0 (en) * | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | T cell production fram RAG inacivated iPSCs |
-
2020
- 2020-08-20 AU AU2020333918A patent/AU2020333918A1/en not_active Abandoned
- 2020-08-20 CA CA3150037A patent/CA3150037A1/en active Pending
- 2020-08-20 MX MX2022001961A patent/MX2022001961A/es unknown
- 2020-08-20 KR KR1020227009201A patent/KR20220047375A/ko active Pending
- 2020-08-20 BR BR112022003083A patent/BR112022003083A2/pt unknown
- 2020-08-20 EP EP20761198.9A patent/EP4017969A1/en not_active Withdrawn
- 2020-08-20 US US17/630,880 patent/US20220275335A1/en not_active Abandoned
- 2020-08-20 CN CN202080059143.3A patent/CN114341349A/zh active Pending
- 2020-08-20 WO PCT/EP2020/073407 patent/WO2021032855A1/en not_active Ceased
- 2020-08-20 JP JP2022510803A patent/JP2022545415A/ja active Pending
-
2022
- 2022-02-14 IL IL290602A patent/IL290602A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022545415A (ja) | 2022-10-27 |
| US20220275335A1 (en) | 2022-09-01 |
| CA3150037A1 (en) | 2021-02-25 |
| WO2021032855A1 (en) | 2021-02-25 |
| KR20220047375A (ko) | 2022-04-15 |
| CN114341349A (zh) | 2022-04-12 |
| EP4017969A1 (en) | 2022-06-29 |
| AU2020333918A1 (en) | 2022-03-24 |
| BR112022003083A2 (pt) | 2022-08-02 |
| IL290602A (en) | 2022-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001961A (es) | Medio de cultivo para induccion de hematopoyesis. | |
| Cany et al. | Combined IL-15 and IL-12 drives the generation of CD34+-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer | |
| Lian et al. | Efficient differentiation of human pluripotent stem cells to endothelial progenitors via small-molecule activation of WNT signaling | |
| Smigiel et al. | Potent EMT and CSC phenotypes are induced by oncostatin-M in pancreatic cancer | |
| Vodyanik et al. | A mesoderm-derived precursor for mesenchymal stem and endothelial cells | |
| Sim et al. | The IL-2 cytokine family in cancer immunotherapy | |
| Ohnishi et al. | Effect of hypoxia on gene expression of bone marrow-derived mesenchymal stem cells and mononuclear cells | |
| Alizadeh et al. | The multifaceted role of Th17 lymphocytes and their associated cytokines in cancer | |
| Uenishi et al. | Tenascin C promotes hematoendothelial development and T lymphoid commitment from human pluripotent stem cells in chemically defined conditions | |
| Cutolo et al. | Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis. | |
| EA202190624A1 (ru) | Car-экспрессирующие т-клетки и car-экспрессирующий вектор | |
| Karagiannidis et al. | G-CSF and G-CSFR modulate CD4 and CD8 T cell responses to promote colon tumor growth and are potential therapeutic targets | |
| Desplat et al. | Hypoxia modifies proliferation and differentiation of CD34+ CML cells | |
| Lu et al. | Robust generation of hemangioblastic progenitors from human embryonic stem cells | |
| Castellone et al. | RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2) | |
| Ribatti et al. | Multiple myeloma as a model for the role of bone marrow niches in the control of angiogenesis | |
| Sharma et al. | Ally to adversary: mesenchymal stem cells and their transformation in leukaemia | |
| Pellegrino et al. | Manipulating the tumor immune microenvironment to improve cancer immunotherapy: IGF1R, a promising target | |
| Nowwarote et al. | Role of endogenous basic fibroblast growth factor in stem cells isolated from human exfoliated deciduous teeth | |
| Lepletier et al. | Perspectives for improvement of the thymic microenvironment through manipulation of thymic epithelial cells: a mini-review | |
| Gazitt | Immunologic profiles of effector cells and peripheral blood stem cells mobilized with different hematopoietic growth factors | |
| Forget et al. | Stimulation of Wnt/ss-catenin pathway in human CD8+ T lymphocytes from blood and lung tumors leads to a shared young/memory phenotype | |
| BR112021021996A2 (pt) | Métodos para administração de imunoterapia com receptores de antígeno quimérico | |
| Klein Wolterink et al. | The intrathymic crossroads of T and NK cell differentiation | |
| Lui et al. | Cytokine combinations on the potential for ex vivo expansion of murine hematopoietic stem cells |